Cargando…

Analgesic drug development: time to break the mould

Detalles Bibliográficos
Autor principal:	Woolf, Clifford
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer 2013
Materias:	Invited Speaker Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619983/ http://dx.doi.org/10.1186/1129-2377-14-S1-I2

Ejemplares similares

Drug-drug interactions: it is not only CYP450's which matter
por: Back, David J
Publicado: (2010)

Abstract not submitted at time of publication
Publicado: (2011)

Abstract not submitted at time of publication
Publicado: (2011)

Abstract not submitted at time of publication
Publicado: (2011)

Abstract not submitted at time of publication
Publicado: (2011)

Abstract not submitted at time of publication
Publicado: (2011)

Abstract not submitted at time of publication
Publicado: (2011)

Abstract not submitted at time of publication
Publicado: (2011)

Abstract not submitted at time of publication
Publicado: (2011)

Abstract not submitted at time of publication
Publicado: (2011)

New anti HCV drugs in the pipeline
por: Bourlière, Marc
Publicado: (2010)

Diffusion of new antiretroviral drugs in CSF
por: Aweeka, Francesca
Publicado: (2010)

Evidence-based TDM for antiretroviral drugs
por: Solas, Caroline
Publicado: (2010)

New drug interactions in HIV and HCV
por: Back, David
Publicado: (2012)

Transporters used by parasites as drug targets: tempting but underexploited
por: Staines, Henry
Publicado: (2010)

Rehabilitation from symptomatic drugs overuse: yes, no, may be
por: Tassorelli, Cristina, et al.
Publicado: (2015)

Use of new technologies to detect and understand HIV drug resistance
por: Kozal, Michael J
Publicado: (2010)

INSP-04. Confirmatory adaptive designs for survival trials with several time-to-event endpoints
por: Schmidt, Rene
Publicado: (2022)

Using economic modelling to contribute to the prioritisation and design and clinical trials: ready for prime time
por: Sculpher, Mark
Publicado: (2011)

Regulation of shoot-system development in Populus
por: Brunner, Amy, et al.
Publicado: (2011)

Development of ICD 11: changes and challenges
por: Zafar, A, et al.
Publicado: (2012)

INSP-17. Augmented Drug Delivery for Pediatric Diffuse Midline Glioma using Convection Enhanced Delivery
por: Souweidane, Mark M
Publicado: (2022)

Research and development for the malaria elimination/eradication roadmap
por: Tanner, Marcel, et al.
Publicado: (2010)

ASEAN Health in the post-2015 development agenda
por: Prakongsai, Phusit
Publicado: (2014)

Identification of genes and alleles influencing wood development in Eucalyptus
por: Southerton, Simon, et al.
Publicado: (2011)

S48. Biomarker development for ipilimumab and prostate GVAX treatment
por: de Gruijl, T, et al.
Publicado: (2014)

INSP-05. Development of fast cortical rhythms in health and mental disease
por: Hanganu-Opatz, Ileana
Publicado: (2022)

PReS13-SPK-1107: Development of an academic pediatric rheumatology program
por: Laxer, R
Publicado: (2013)

Development of an attenuated sporozoite vaccine to prevent and eliminate Plasmodium falciparum malaria
por: Billingsley, Peter F
Publicado: (2010)

Developing sub-acute, non-acute and special groups in the universal grouper
por: Aljunid, Syed Mohamed
Publicado: (2012)

Developing sub-acute and non-acute Casemix classification: the Thailand experience
por: Pannarunothai, Supasit
Publicado: (2012)

PReS13-SPK-1137: New developments in our care & understanding of JIA
por: Beresford, MW
Publicado: (2013)

PReS13-SPK-1478: New developments in our care & understanding of JIA
por: Wedderburn, L
Publicado: (2013)

Division of labor: multiple and specialized controls of vegetative growth and development in a poplar tree
por: Busov, Victor, et al.
Publicado: (2011)

Ethylene signaling via Ethylene Response Factors (ERFs) modifies wood development in hybrid aspen
por: Felten, Judith, et al.
Publicado: (2011)

A novel drug for uncomplicated malaria: targeted high throughput screening (HTS) against the type II NADH:ubiquinone oxidoreductase (PfNdh2) of Plasmodium falciparum
por: Ward, Steve A, et al.
Publicado: (2010)

S49. Clinical activity and development of biomarkers for an engineered anti PDL1 antibody MPDL3280A
por: Cha, E
Publicado: (2014)

INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.
por: Jonchere, Barbara, et al.
Publicado: (2022)

INSP-06. Recent advances in improving neuropsychological outcomes for paediatric brain tumour patients - Are we entering a new era?
por: Mabbott, Donald
Publicado: (2022)

INSP-08. Cerebellar mutism syndrome: incidence, symptoms, risk factors, prognosis. Results and future perspectives from the Nordic-European study of the cerebellar mutism syndrome
por: Sehested, Astrid, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_chghvn32keotpnbda3qrs5h4en